View Item 

Show simple item record

Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer

dc.contributor.authorNeidhart, Jamesen_US
dc.contributor.authorDallaire, Brianen_US
dc.contributor.authorSisk, Reginaen_US
dc.contributor.authorGyves, John W.en_US
dc.contributor.authorMoore, Malcolmen_US
dc.contributor.authorMaroun, Jeanen_US
dc.contributor.authorRobert, Franciscoen_US
dc.contributor.authorNatale, Ronald B.en_US
dc.date.accessioned2006-09-11T15:45:00Z
dc.date.available2006-09-11T15:45:00Z
dc.date.issued1993-02en_US
dc.identifier.citationMoore, Malcolm; Maroun, Jean; Robert, Francisco; Natale, Ronald; Neidhart, James; Dallaire, Brian; Sisk, Regina; Gyves, John; (1993). "Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer." Investigational New Drugs 11(1): 61-65. <http://hdl.handle.net/2027.42/45168>en_US
dc.identifier.issn0167-6997en_US
dc.identifier.issn1573-0646en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45168
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8349438&dopt=citationen_US
dc.description.abstractEighty-six patients with advanced colorectal, gastric or pancreatic carcinoma and no prior exposure to chemotherapy were treated with brequinar sodium. Brequinar was administered at a median weekly dose of 1200 mg/m 2 intravenously. The toxicity was moderate, with thirty patients (35%) experiencing grade 3 or 4 toxicity. Objective responses were observed in 1/32 evaluable colorectal and 2/29 evaluable gastric carcinoma patients. There were no objective responses in 17 evaluable pancreatic cancer patients. We conclude that, at this dose and schedule, brequinar does not have sufficient activity in these gastrointestinal malignancies to warrant further evaluation.en_US
dc.format.extent312155 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherGastrointestinal Carcinomaen_US
dc.subject.otherBrequinar Sodiumen_US
dc.subject.otherPhase IIen_US
dc.titleMulticenter phase II study of brequinar sodium in patients with advanced gastrointestinal canceren_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherUniversity of New Mexico Cancer Center, Albuquerque, NMen_US
dc.contributor.affiliationotherThe DuPont Pharmaceutical Co., Wilmington, DE, USAen_US
dc.contributor.affiliationotherThe DuPont Pharmaceutical Co., Wilmington, DE, USAen_US
dc.contributor.affiliationotherThe DuPont Pharmaceutical Co., Wilmington, DE, USAen_US
dc.contributor.affiliationotherPrincess Margaret Hospital, Toronto, Canen_US
dc.contributor.affiliationotherOttawa Regional Cancer Center, Ottawa, Canen_US
dc.contributor.affiliationotherSan Juan Veterans' Hospital, San Juan Puerto Rico; University of Alabama at Birmingham, Birmingham, AL, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid8349438en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45168/1/10637_2004_Article_BF00873913.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00873913en_US
dc.identifier.sourceInvestigational New Drugsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10637_2004_Article_BF00873913.pdf
Size:
304.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.